CN1709860A - 苯亚甲基茚酮和苄基茚酮类衍生物及制备方法和用途 - Google Patents
苯亚甲基茚酮和苄基茚酮类衍生物及制备方法和用途 Download PDFInfo
- Publication number
- CN1709860A CN1709860A CNA2005100504019A CN200510050401A CN1709860A CN 1709860 A CN1709860 A CN 1709860A CN A2005100504019 A CNA2005100504019 A CN A2005100504019A CN 200510050401 A CN200510050401 A CN 200510050401A CN 1709860 A CN1709860 A CN 1709860A
- Authority
- CN
- China
- Prior art keywords
- indone
- methyl
- benzyl
- amine
- ben yajiaji
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Benzal Chemical class 0.000 title claims abstract description 44
- SNWQUNCRDLUDEX-UHFFFAOYSA-N inden-1-one Chemical compound C1=CC=C2C(=O)C=CC2=C1 SNWQUNCRDLUDEX-UHFFFAOYSA-N 0.000 title claims description 24
- 238000000034 method Methods 0.000 title abstract description 47
- 239000003814 drug Substances 0.000 claims abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
- 206010036631 Presenile dementia Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 32
- 229940095102 methyl benzoate Drugs 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 19
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 claims description 8
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 5
- 150000003053 piperidines Chemical class 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- WIHIUTUAHOZVLE-UHFFFAOYSA-N 1,3-diethoxypropan-2-ol Chemical compound CCOCC(O)COCC WIHIUTUAHOZVLE-UHFFFAOYSA-N 0.000 claims description 4
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 claims description 4
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 150000003335 secondary amines Chemical class 0.000 claims description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 2
- 150000003935 benzaldehydes Chemical class 0.000 claims description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- CPXCDEMFNPKOEF-UHFFFAOYSA-N methyl 3-methylbenzoate Chemical class COC(=O)C1=CC=CC(C)=C1 CPXCDEMFNPKOEF-UHFFFAOYSA-N 0.000 claims description 2
- QSSJZLPUHJDYKF-UHFFFAOYSA-N methyl 4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1 QSSJZLPUHJDYKF-UHFFFAOYSA-N 0.000 claims description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 238000006482 condensation reaction Methods 0.000 claims 2
- WVWZECQNFWFVFW-UHFFFAOYSA-N methyl 2-methylbenzoate Chemical compound COC(=O)C1=CC=CC=C1C WVWZECQNFWFVFW-UHFFFAOYSA-N 0.000 claims 1
- FTXYLCJMXBWTQT-UHFFFAOYSA-N 2-benzylinden-1-one Chemical compound C=1C2=CC=CC=C2C(=O)C=1CC1=CC=CC=C1 FTXYLCJMXBWTQT-UHFFFAOYSA-N 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000007787 solid Substances 0.000 description 29
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 102000012440 Acetylcholinesterase Human genes 0.000 description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 description 5
- 229910010082 LiAlH Inorganic materials 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 229940022698 acetylcholinesterase Drugs 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 239000003513 alkali Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- APLHEOBEIBHCHW-YQEJDHNASA-N Selagine Natural products O=C1NC2=C([C@]3(N)/C(=C/C)/[C@@H](CC(C)=C3)C2)C=C1 APLHEOBEIBHCHW-YQEJDHNASA-N 0.000 description 2
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 239000002329 esterase inhibitor Substances 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- AKAKCEPCLVSYHK-UHFFFAOYSA-N 2-benzyl-2,3-dihydroinden-1-one Chemical class C1C2=CC=CC=C2C(=O)C1CC1=CC=CC=C1 AKAKCEPCLVSYHK-UHFFFAOYSA-N 0.000 description 1
- VNZLRRDCSJLAPP-UHFFFAOYSA-N 2-phenoxy-2,3-dihydroinden-1-one Chemical class C1C2=CC=CC=C2C(=O)C1OC1=CC=CC=C1 VNZLRRDCSJLAPP-UHFFFAOYSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- 101100379081 Emericella variicolor andC gene Proteins 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供苯亚甲基茚酮和苄基茚酮类化合物,通过以下步骤制得:以间甲基苯甲酸甲酯或对甲基苯甲酸甲酯为原料,用N-溴代丁二酰亚胺对苄基进行溴代得到II,然后用不同的二级胺与它进行取代反应,得到胺化产物III,再用LiAlH4-Et2NH体系选择性还原苯甲酸酯得到取代苯甲醛IV,将它与5,6-二甲氧基茚酮在碱性条件下缩合制得苯亚甲基茚酮衍生物VI,再经过氢化还原双键得到苄基茚酮衍生物VII。本发明提供的苯亚甲基茚酮和苄基茚酮类衍生物,在制备治疗早老性痴呆疾病药物中的应用,其生理可接受的盐在制备治疗早老性痴呆疾病药物中的应用。本发明的苯亚甲基茚酮和苄基茚酮类化合物具有如上结构通式。
Description
技术领域
本发明属化合物制备方法,主要涉及苯亚甲基茚酮和苄基茚酮类衍生物及制备方法和用途。
背景技术
早老性痴呆(Alzheimer’s disease,AD)作为一种神经退行性疾病,已经成为当今社会中严重威胁老年人健康的重大疾病之一,因此AD治疗药物的研究也是目前新药研究的热点之一。
目前,乙酰胆碱酯酶抑制剂(AchEI)在治疗AD的临床用药中疗效最为确切、应用范围最广,此类药物已上市的有他克林(Tacrine)、多奈哌齐(Donepezil)、加兰他敏(Galanthamine)、利伐司替明(Rivastigmine)和石杉碱甲(Huprine)等,而且尚有几十种药物处于临床前或正在作临床研究。
中国专利《苯氧基茚酮类化合物及其制备方法和用途》,申请号200410016180.9,中国专利《含氨苯氧茚酮类衍生物及制备方法和用途》,申请号200510016180.9,设计合成了苯氧茚酮类衍生物,并进行了初步的药理学试验,结果表明该类化合物具有明显的抑制乙酰胆碱酯酶活性,是有前景的乙酰胆碱酯酶抑制剂,为早老性痴呆(AD)治疗药物的研究提供了新的思路。
发明内容
在上述中国专利《苯氧基茚酮类化合物及其制备方法和用途》和《含氨苯氧茚酮类衍生物及制备方法和用途》的基础上,本发明对其中的连接链进行改变,分别用不饱和碳链(=CH)和亚甲基(CH2)代替原先的氧原子(O),得到新的苯亚甲基茚酮和苄基茚酮类衍生物,并对合成的化合物进行抑制乙酰胆碱酯酶(AChE)活性测试,结果显示,新合成的苯亚甲基茚酮和苄基茚酮类衍生物都拥有较强的抑制AChE活性,绝大多数化合物的IC50小于1.0μmol/L,其中两个化合物35、36的IC50分别达到34.8nmol/L和44.8nmol/L,说明它们是有前景的乙酰胆碱酯酶抑制剂,有可能成为AD的候选药物。
本发明目的是用碳原子链替代苯氧基茚酮类化合物中的氧原子,得到活性更佳的侯选化合物,为该类化合物进入临床研究提供物质基础,为早老性痴呆的治疗药物研究提供物质条件。
本发明提供的苯亚甲基茚酮和苄基茚酮类化合物具有如下结构通式
上述苯亚甲基茚酮和苄基茚酮类衍生物,当X=CH2和=CH时,当胺甲基在碳原子的间位取代时,N(R1R2)为二甲胺基、甲乙胺基、二乙胺基、吡咯烷基、哌啶基和吗啉基其中一种。
上述苯亚甲基茚酮和苄基茚酮类衍生物,当X=CH2和=CHO时,当胺甲基在碳原子的对位取代时,N(R1R2)为二甲胺基、甲乙胺基、二乙胺基、吡咯烷基、哌啶基和吗啉基其中一种。
上述目标化合物可通过以下步骤制得:以间甲基苯甲酸甲酯或对甲基苯甲酸甲酯(I)为原料,用N-溴代丁二酰亚胺(NBS)对苄基进行溴代,得到II,然后用不同的二级胺与它进行取代反应,得到胺化产物III,再用LiAlH4-Et2NH体系选择性还原苯甲酸酯得到取代苯甲醛IV,将它与5,6-二甲氧基茚酮在碱性条件下缩合制得苯亚甲基茚酮衍生物VI,再经过氢化还原双键得到苄基茚酮衍生物VII。
上面反应式是用于制备目标化合物VI、VII的反应式。其中化合物I可直接购买,化合物V(5,6-二甲氧基-1-茚酮)可按文献方法(John K,J.Am.Chem.Soc.1953,75,1891-1894)制得。
根据上述反应式,化合物I先用N-溴代丁二酰亚胺(NBS)进行甲基的溴代反应,得到3或4-溴甲基-苯甲酸酯(化合物II);该反应一般在惰性溶剂中进行,如CCl4,石油醚(60-90℃)等,反应通常在60-100℃之间进行。然后将化合物II与二甲基胺、二乙基胺、吡咯烷等二级胺发生取代反应,得到相应的3或4-胺甲基-苯甲酸甲酯(化合物III),所用溶剂一般为乙腈、氯仿、二氯甲烷等,一般在室温下反应。LiAlH4和二乙胺形成的复合试剂可以对化合物III进行选择性还原,制得相应的3或4-胺甲基-苯甲醛(化合物IV),所用的溶剂主要是四氢呋喃(THF)、乙醚、二氧六环等,反应温度控制在0-30℃之间。碱性条件下,化合物IV与化合物V(5,6-二甲氧基-1-茚酮)发生Aldol缩合生成苯亚甲基茚酮衍生物(化合物VI),所用溶剂主要选用甲醇、乙醇、四氢呋喃(THF)、甲醇-水、THF-水、乙醇-水等,所用的碱包括有机碱和无机碱,有机碱主要选用吡啶、三乙胺、哌啶等,无机碱如:碳酸钾、碳酸钠、氢氧化钾、氢氧化钠、氢化钠等,反应通常在10-100℃之间进行。然后,化合物VI用5%Pd/C进行选择性催化氢化得到目标化合物VII,所用的溶剂为THF、乙酸乙酯、二氧六环、甲醇、乙醇等,反应温度通常在10-60℃之间,所得产物经过柱层析可得纯产物。
本发明提供的苯亚甲基茚酮和苄基茚酮类衍生物,在制备治疗早老性痴呆疾病药物中的应用。
本发明提供的苯亚甲基茚酮和苄基茚酮类衍生物,其生理可接受的盐在制备治疗早老性痴呆疾病药物中的应用。
具体实施方式
下面结合实施例对本发明作进一步的说明。
实施例1:3-溴甲基-苯甲酸甲酯
将15.0g(0.1mol)3-甲基-苯甲酸甲酯、20.0g(0.11mol)N-溴代丁二酰亚胺和150mL CCl4投入反应瓶中,升温至回流,反应4h,冷却至室温,抽滤除去固体,并用少量CCl4洗涤,减压回收溶剂,得到21.6g淡黄色油状物,收率94.3%。
实施例2:4-溴甲基-苯甲酸甲酯
操作过程同实施例1,只是用4-甲基-苯甲酸甲酯替代3-甲基-苯甲酸甲酯,得到20.9g淡黄色固体,收率91.3%,熔点:52~54℃。
实施例3:3-二甲胺基甲基-苯甲酸甲酯
2.29g(0.01mol)3-溴甲基-苯甲酸甲酯溶于20mL CH2Cl2中,在室温下滴加3.1mL(0.02mol)二甲胺水溶液(33%),滴加完毕后,继续反应2h,减压回收溶剂和过量二甲胺,残留物中加入20mL 2N盐酸和15mL乙酸乙酯,分出有机层,弃去。水层用浓氨水调节pH至10,乙酸乙酯(20mL×3)提取,合并有机层,饱和NaCl洗涤,无水Na2SO4干燥,回收溶剂,用硅胶柱层析(石油醚∶乙酸乙酯=5∶1),得到油状物1.11g,收率57.5%。1H-NMR(δ,CDCl3):7.92-7.96(m,2H,H-2and H-6),7.49-7.51(d,1H,H-4,J=7.2Hz),7.37-7.39(t,1H,J=7.6Hz,H-5),3.90(s,3H,OCH3),3.45(s,2H,CH2),2.23(s,6H,2N-CH3);IR(KBr):3021,2949,2855,2817,1725,1589,1434,1286,749,694cm-1.
实施例4:3-甲乙胺基甲基-苯甲酸甲酯
操作过程同实施例3,只是用甲基乙基胺代替二甲胺,得到油状物1.07g,收率51.7%。1H-NMR(δ,CDCl3):7.97(s,1H,H-2),7.90-7.91(d,1H,J=7.6Hz,H-6),7.51-7.53(d,1H,J=7.6Hz,H-4),7.36-7.39(t,1H,J=7.6Hz,H-5),3.90(s,3H,OCH3),3.51(s,2H,benzylic-CH2),2.43-2.45(q,2H,J=6.8Hz,CH2-CH3),2.17(s,3H,N-CH3),1.07-1.11(t,3H,J=6.8Hz,CH2-CH3);IR(KBr):3025,2971,2950,2839,1725,1589,1434,1285,748,693cm-1.
实施例5:3-二乙胺基甲基-苯甲酸甲酯
操作过程同实施例3,只是用二乙胺代替二甲胺,得到油状物1.68g,收率76.0%;1H-NMR(δ,CDCl3):7.99(s,1H,H-2),7.90-7.92(d,1H,J=7.6Hz,H-6),7.55-7.57(d,1H,J=7.6Hz,H-4),7.36-7.40(t,1H,J=7.6Hz,H-5),3.91(s,3H,OCH3),3.60(s,2H,benzylic-CH2),2.49-2.55(q,4H,J=7.6Hz,2×CH2),1.02-1.06(t,6H,J=7.6Hz,2×CH3);IR(KBr):3024,2970,2873,1725,1589,1433,1284,745,692cm-1.
实施例6:3-吡咯烷-1-基甲基-苯甲酸甲酯
操作过程同实施例3,只是用吡咯烷代替二甲胺,得到油状物1.52g,收率69.4%;1H-NMR(δ,CDCl3):8.00(s,1H,H-2),7.92-7.93(d,1H,J=7.6Hz,H-6),7.54-7.56(d,1H,J=8.0Hz,H-4),7.37-7.40(t,1H,J=7.6Hz,H-5),3.91(s,3H,OCH3),3.65(s,2H,benzylic-CH2),2.49-2.52(m,4H,pyrrolidine-CH2,H-2’andH-5’),1.77-1.80(m,4H,H-3’and H-4’);IR(KBr):3018,2951,2870,1723,1588,1433,1283,749,699cm-1
实施例7:3-哌啶-1-基甲基-苯甲酸甲酯
操作过程同实施例3,只是用哌啶代替二甲胺,得到1.84g油状物,收率78.9%。1H-NMR(δ,CDCl3):7.97(s,1H,H-2),7.91-7.93(d,1H,J=7.6Hz,H-6),7.53-7.55(d,1H,J=8.0Hz,H-4),7.36-7.40(t,1H,J=7.6Hz,H-5),3.91(s,3H,OCH3),3.50(s,2H,benzylic-CH2),2.37(m,4H,piperidine-CH2,H-2’and H-6’),1.54-1.60(m,4H,H-3’and H-5’),1.43-1.45(m,2H,H-4’);IR(KBr):3026,2935,2853,1725,1589,1434,1285,748,694cm-1.
实施例8:3-吗啉-4-基甲基-苯甲酸甲酯
操作过程同实施例3,只是用吗啉代替二甲胺,得到1.89g油状物,收率80.4%。1H-NMR(δ,CDCl3):7.99(s,1H,H-2),7.93-7.95(d,1H,J=7.6Hz,H-6),7.54-7.56(d,1H,J=7.2Hz,H-4),7.38-7.42(t,1H,J=7.6Hz,H-5),3.92(s,3H,OCH3),3.70-3.72(t,4H,J=4.8Hz,morpholine-CH2,H-2’and H-6’),3.54(s,2H,benzylic-CH2),2.44-2.46(m,4H,H-3’and H-5’);IR(KBr):3024,2953,2853,1723,1589,1433,1282,749,695cm-1.
实施例9:4-二甲胺基甲基-苯甲酸甲酯
2.29g(0.01mol)4-溴甲基-苯甲酸甲酯72溶于20mL乙腈中,在室温下滴加3.1mL(0.02mol)33%二甲胺溶液,滴加完毕后,继续室温反应2h,减压回收溶剂,残留物中加入20mL 2N盐酸和15mL乙酸乙酯,分出有机层,弃去。水层用浓氨水调节pH至10,乙酸乙酯(20mL×3)提取,合并有机层,饱和NaCl洗涤,无水Na2SO4干燥,回收溶剂,柱层析后得到0.97g油状物,收率50.4%;1H-NMR(δ,CDCl3):7.99-8.01(d,2H,J=8.0Hz,H-2and H-6),7.38-7.40(d,2H,J=8.0Hz,H-3and H-5),3.91(s,3H,OCH3),3.47(s,2H,benzylic-CH2),2.25(s,6H,2×N-CH3);IR(KBr):3012,2976,2817,1723,1611,1435,1279,865cm-1.
实施例10:4-甲乙胺基甲基-苯甲酸甲酯
操作过程同实施例9,只是用甲基乙基胺代替二甲胺,得到油状物1.12g,收率54.1%;1H-NMR(δ,CDCl3):7.97-7.99(d,2H,J=8.0Hz,H-2and H-6),7.38-7.40(d,2H,J=8.0Hz,H-3and H-5),3.90(s,3H,OCH3),3.53(s,2H,benzylic-CH2),2.42-2.47(q,2H,J=7.2Hz,CH2-CH3),2.19(s,3H,N-CH3),1.08-1.11(t,3H,J=7.2Hz,CH2-CH3);IR(KBr):3016,2971,2842,1725,1611,1435,1278,859cm-1.
实施例11:4-二乙胺基甲基-苯甲酸甲酯
操作过程同实施例9,只是用二乙基胺代替二甲胺,柱层析后得到油状物1.52g,收率68.7%;1H-NMR(δ,CDCl3):7.97-7.99(d,2H,J=8.0Hz,H-2andH-6),7.41-7.43(d,2H,J=8.0Hz,H-3and H-5),3.91(s,3H,OCH3),3.60(s,2H,benzylic-CH2),2.49-2.54(q,4H,J=7.2Hz,2×CH2),1.02-1.06(t,6H,J=7.2Hz,2×CH3);IR(KBr):3047,2970,2873,1724,1611,1435,1278,858cm-1.
实施例12:4-吡咯烷-1-基甲基-苯甲酸甲酯
操作过程同实施例9,只是用吡咯烷代替二甲胺,柱层析后得到油状物1.31g,收率59.8%;1H-NMR(δ,CDCl3):7.98-8.00(d,2H,J=8.0Hz,H-2andH-6),7.40-7.42(d,2H,J=8.0Hz,H-3and H-5),3.91(s,3H,OCH3),3.66(s,2H,benzylic-CH2),2.49-2.52(m,4H,pyrrolidine-CH2,H-2’and H-5’),1.77-1.81(m,4H,H-3’and H-4’);IR(KBr):3027,2954,2783,1723,1612,1435,1278,855cm-1.
实施例13:4-哌啶-1-基甲基-苯甲酸甲酯
操作过程同实施例9,只是用哌啶代替二甲胺,柱层析后得到油状物1.79g,收率76.8%;1H-NMR(δ,CDCl3):7.97-7.99(d,2H,J=8.0Hz,H-2andH-6),7.39-7.41(d,2H,J=8.0Hz,H-3and H-5),3.91(s,3H,OCH3),3.51(s,2H,benzylic-CH2),2.37(m,4H,piperidine-CH2,H-2’and H-6’),1.55-1.60(m,4H,H-3’and H-5’),1.43-1.45(m,2H,H-4’);IR(KBr):3031,2935,2853,1724,1612,1435,1279,866cm-1.
实施例14:4-吗啉-4-基甲基-苯甲酸甲酯
操作过程同实施例9,只是用吗啉代替二甲胺,柱层析后得到油状物1.84g,收率78.5%;1H-NMR(δ,CDCl3):7.98-8.00(d,2H,J=8.0Hz,H-2and H-6),7.41-7.43(d,2H,J=8.0Hz,H-3and H-5),3.91(s,3H,OCH3),3.70-3.73(m,4H,morpholine-CH2,H-2’and H-6’),3.55(s,2H,benzylic-CH2),2.44-2.46(m,4H,H-3’and H-5’);IR(KBr):3026,2953,2853,1722,1612,1435,1279,868cm-1.
实施例15:3-二甲胺基甲基-苯甲醛
将78mg(2.0mmol)LiAlH4(97%)和0.41mL(4.0mmol)二乙胺加到10mL无水乙醚中,冰浴下加入0.39g(2.0mmol)3-二甲胺基甲基-苯甲酸甲酯,继续反应1h,加入10mL冰水,抽滤除去固体,水层用乙醚(10mL×3)提取,合并乙醚层,饱和NaCl溶液洗涤,无水Na2SO4干燥,回收溶剂,残留物经柱层析后得到油状物150mg,收率46.0%。1H-NMR(δ,CDCl3):10.02(s,1H,CHO),7.83(s,1H,H-2),7.78-7.80(d,1H,J=7.6Hz,H-6),7.59-7.61(d,1H,J=7.6Hz,H-4),7.47-7.51(t,1H,J=7.6Hz,H-5),3.50(s,2H,CH2),2.26(s,6H,2×N-CH3);IR(KBr):3021,2942,2855,2818,2725,1697,1589,1457,797,691cm-1..
实施例16:3-甲乙胺基甲基-苯甲醛
操作过程同实施例15,只是用3-甲乙胺基甲基-苯甲酸甲酯代替3-二甲胺基甲基-苯甲酸甲酯,得到油状物159mg,收率44.9%;1H-NMR(δ,CDCl3):10.02(s,1H,CHO),7.84(s,1H,H-2),7.77-7.79(d,1H,J=8.0Hz,H-6),7.61-7.62(d,1H,J=7.6Hz,H-4),7.47-7.51(t,1H,J=7.6Hz,H-5),3.56(s,2H,benzylic-CH2),2.45-2.50(q,4H,J=7.2Hz,2×CH2),2.20(s,3H,N-CH3),1.10-1.13(t,3H,J=7.2Hz,2×CH3);IR(KBr):3020,2970,2924,2848,2726,1699,1604,1588,1450,784,690cm-1.
实施例17:3-二乙胺基甲基-苯甲醛
操作过程同实施例15,只是用3-二乙胺基甲基-苯甲酸甲酯代替3-二甲胺基甲基-苯甲酸甲酯,得到油状物201mg,收率52.8%;1H-NMR(δ,CDCl3):10.02(s,1H,CHO),7.86(s,1H,H-2),7.75-7.77(d,1H,J=7.6Hz,H-6),7.62-7.64(d,1H,J=7.6Hz,H-4),7.45-7.49(t,1H,J=7.6Hz,H-5),3.63(s,2H,benzylic-CH2),2.51-2.56(q,4H,J=6.8Hz,2×CH2),1.03-1.06(t,6H,J=6.8Hz,2×CH3);IR(KBr):3024,2970,2934,2724,1703,1604,1588,1449,785,689cm-1.
实施例18:3-吡咯烷-1-基甲基-苯甲醛
将78mg(2.0mmol)LiAlH4(97%)和0.41mL(4.0mmol)二乙胺加到10mL无水THF中,冰浴下加入0.44g(2.0mmol)3-吡咯烷-1-基甲基-苯甲酸甲酯,继续反应1h,然后加入5mL冰水,抽滤除去固体,回收溶剂,残留物用乙醚(10mL×3)提取,饱和NaCl溶液洗涤,无水Na2SO4干燥,回收溶剂,残留物经柱层析后得到油状物180mg,收率47.6%;1H-NMR(δ,CDCl3):10.02(s,1H,CHO),7.86(s,1H,H-2),7.77-7.79(d,1H,J=7.6Hz,H-6),7.62-7.64(d,1H,J=7.6Hz,H-4),7.46-7.50(t,1H,J=7.2Hz,H-5),3.69(s,2H,benzylic-CH2),2.51-2.54(m,4H,pyrrolidine-CH2,H-2’and H-5’),1.79-1.82(m,4H,H-3’andH-4’);IR(KBr):3026,2962,2927,2732,1699,1605,1588,1460,783,692cm-1.
实施例19:3-哌啶-1-基甲基-苯甲醛
操作过程同实施例18,只是用3-哌啶基-1-基甲基-苯甲酸甲酯代替3-吡咯烷-1-基甲基-苯甲酸甲酯,得到油状物178mg,收率43.9%;1H-NMR(δ,CDCl3):10.02(s,1H,CHO),7.83(s,1H,H-2),7.76-7.78(d,1H,J=7.6Hz,H-6),7.61-7.63(d,1H,J=7.6Hz,H-4),7.46-7.49(t,1H,J=7.6Hz,H-5),3.54(s,2H,benzylic-CH2),2.39(m,4H,piperidine-CH2,H-2’and H-6’),1.56-1.61(m,4H,H-3’and H-5’),1.44-1.45(m,2H,H-4’);IR(KBr):3031,2935,2852,2723,1699,1604,1588,1450,801,691cm-1.
实施例20:3-吗啉-4-基甲基-苯甲醛
操作过程同实施例18,只是用3-吗啉-4-基甲基-苯甲酸甲酯代替3-吡咯烷-1-基甲基-苯甲酸甲酯,得到油状物193mg,收率47.0%;1H-NMR(δ,CDCl3):10.03(s,1H,CHO),7.87(s,1H,H-2),7.78-7.80(d,1H,J=8.0Hz,H-6),7.62-7.64(d,1H,J=7.6Hz,H-4),7.48-7.52(t,1H,J=7.6Hz,H-5),3.71-3.73(m,4H,morpholine-CH2,H-2’and H-6’),3.57(s,2H,benzylic-CH2),2.46(m,4H,H-3’and H-5’);IR(KBr):3024,2956,2853,2734,1699,1604,1588,1455,783,691cm-1.
实施例21:4-二甲胺基甲基-苯甲醛
操作过程同实施例15,只是用4-二甲胺基甲基-苯甲酸甲酯代替3-二甲胺基甲基-苯甲酸甲酯,得到油状物145mg,收率44.4%;1H-NMR(δ,CDCl3):10.03(s,1H,CHO),7.84-7.86(d,2H,J=7.6Hz,H-2 and H-6),7.48-7.50(d,2H,J=7.6Hz,H-3and H-5),3.50(s,2H,benzylic-CH2),2.26(s,6H,2×N-CH3);IR(KBr):3006,2943,2849,2731,1700,1607,1577,1456,817cm-1.
实施例22:4-甲乙胺基甲基-苯甲醛
操作过程同实施例15,只是用4-甲乙胺基甲基-苯甲酸甲酯代替3-二甲胺基甲基-苯甲酸甲酯,得到油状物169mg,收率47.8%;1H-NMR(δ,CDCl3):10.00(s,1H,CHO),7.83-7.85(d,2H,J=7.6Hz,H-2and H-6),7.50-7.52(d,2H,J=8.0Hz,H-3and H-5),3.57(s,2H,benzylic-CH2),2.45-2.50(q,2H,J=7.2Hz,CH2),2.21(s,3H,N-CH3),1.10-1.13(t,3H,J=7.2Hz,CH3);IR(KBr):3031,2969,2926,2847,2735,1700,1607,1577,1456,835cm-1.
实施例23:4-二乙胺基甲基-苯甲醛
操作过程同实施例15,只是用4-二乙胺基甲基-苯甲酸甲酯代替3-二甲胺基甲基-苯甲酸甲酯,得到油状物211mg,收率55.4%;1H-NMR(δ,CDCl3):10.00(s,1H,CHO),7.82-7.84(d,2H,J=8.0Hz,H-2and H-6),7.52-7.54(d,2H,J=8.0Hz,H-3and H-5),3.64(s,2H,benzylic-CH2),2.51-2.56(q,4H,J=7.2Hz,2×CH2),1.03-1.07(t,6H,J=7.2Hz,2×CH3);IR(KBr):3014,2969,2934,2730,1701,1607,1577,1454,831cm-1.
实施例24:4-吡咯烷-1-基甲基-苯甲醛
操作过程同实施例15,只是用4-吡咯烷-1-基甲基-苯甲酸甲酯代替3-二甲胺基甲基-苯甲酸甲酯,得到油状物204mg,收率54.1%;1H-NMR(δ,CDCl3):10.00(s,1H,CHO),7.83-7.85(d,2H,J=7.6Hz,H-2and H-6),7.51-7.52(d,2H,J=7.6Hz,H-3and H-5),3.70(s,2H,benzylic-CH2),2.52-2.55(m,4H,pyrrolidine-CH2,H-2’and H-5’),1.79-1.81(m,4H,H-3’and H-4’);IR(KBr):3024,2964,2875,2733,1699,1607,1577,1461,825cm-1.
实施例25:4-哌啶-1-基甲基-苯甲醛
操作过程同实施例15,只是用4-哌啶-1-基甲基-苯甲酸甲酯代替3-二甲胺基甲基-苯甲酸甲酯,经柱层析后得到油状物198mg,收率48.8%;1H-NMR(δ,CDCl3):10.00(s,1H,CHO),7.82-7.84(d,2H,J=7.2Hz,H-2andH-6),7.49-7.51(d,2H,J=7.2Hz,H-3and H-5),3.55(s,2H,benzylic-CH2),2.39(m,4H,piperidine-CH2,H-2’and H-6’),1.57-1.60(m,4H,H-3’and H-5’),1.44(m,2H,H-4’);IR(KBr):3024,2935,2852,2732,1702,1607,1577,863cm-1.
实施例26:4-吗啉-4-基甲基-苯甲醛
操作过程同实施例15,只是用4-吗啉-4-基甲基-苯甲酸甲酯代替3-二甲胺基甲基-苯甲酸甲酯,得到白色固体228mg,熔点42~44℃:收率55.6%。1H-NMR(δ,CDCl3):10.01(s,1H,CHO),7.84-7.86(d,2H,J=8.0Hz,H-2andH-6),7.51-7.53(d,2H,J=8.0Hz,H-3and H-5),3.72-3.74(m,4H,morpholine-CH2,H-2’and H-6’),3.58(s,2H,benzylic-CH2),2.46-2.48(m,4H,H-3’and H-5’);IR(KBr):3026,2963,2927,2734,1689,1605,1575,1453,861cm-1.
实施例27:5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮
将0.16g(1.0mmol)3-二甲胺基甲基-苯甲醛、0.21g(1.1mmol)5,6-二甲氧基茚酮、10mL甲醇和84mg(1.5mmol)KOH投入反应瓶中,室温反应3h,减压回收溶剂,残留物中加入20mL 2N盐酸和20mL乙酸乙酯,分出有机层,弃去;水层用浓氨水调节pH至10,乙酸乙酯(20mL×3)提取,合并有机层,饱和NaCl溶液洗涤,无水Na2SO4干燥,回收溶剂,残留物用硅胶柱层析,洗脱剂为:石油醚∶乙酸乙酯∶三乙胺=10∶5∶1,得到0.27g淡黄色固体,收率80.1%,熔点:96~98℃。1H-NMR(δ,CDCl3):7.56-7.59(m,3H,H-7,H-2’andH-4’),7.41-7.43(t,1H,J=7.6Hz,H-5’),7.34-7.37(m,2H,H-6’and C=CH),7.00(s,1H,H-4),4.00(s,3H,OCH3),3.98(s,2H,H-3),3.95(s,3H,OCH3),3.49(s,2H,benzylic-CH2),2.28(s,6H,2×N-CH3);IR(KBr):3066,2940,2816,1687,1630,1605,1588,1501,1233,806,695cm-1.
实施例28:5,6-二甲氧基-2-(3-甲乙胺基甲基-苯亚甲基)-1-茚酮
操作过程同实施例27,只是用3-甲乙胺基甲基-苯甲醛代替3-二甲胺基甲基-苯甲醛,得到0.28g淡黄色固体,收率79.8%,熔点:75~77℃;1H-NMR(δ,CDCl3):7.61(s,2H,H-7and H-2’),7.55-7.57(d,1H,J=7.6Hz,H-4’),7.39-7.43(t,1H,J=7.6Hz,H-5’),7.35-7.37(m,2H,H-6’andC=CH),7.00(s,1H,H-4),4.00(s,3H,OCH3),3.98(s,2H,H-3),3.96(s,3H,OCH3),3.57(s,2H,benzylic-CH2),2.48-2.53(q,2H,J=7.2Hz,CH2-CH3),2.24(s,3H,N-CH3),1.12-1.15(t,3H,J=7.2Hz,CH2-CH3);IR(KBr):3068,2968,2835,1689,1631,1606,1588,1501,1304,1217,805,695cm-1.
实施例29:5,6-二甲氧基-2-(3-二乙胺基甲基-苯亚甲基)-1-茚酮
将0.19g(1.0mmol)3-二乙胺基甲基-苯甲醛、0.21g(1.1mmol)5,6-二甲氧基茚酮、9mL乙醇和1mL水以及60mg(1.5mmol)NaOH投入反应瓶中,室温反应4小时,减压回收溶剂,残留物中加入20mL 2N盐酸和20mL乙酸乙酯,分出有机层,弃去;水层用浓氨水调节pH至10,乙酸乙酯(20mL×3)提取,合并有机层,饱和NaCl溶液洗涤,无水Na2SO4干燥,回收溶剂,残留物用硅胶柱层析,洗脱剂为:石油醚∶乙酸乙酯∶三乙胺=10∶5∶1,得到0.29g淡黄色固体,收率79.4%,熔点:78~80℃。1H-NMR(δ,CDCl3):7.64(s,1H,H-7),7.61(s,1H,H-2’),7.53-7.55(d,1H,J=6.8Hz H-4’),7.36-7.41(m,3H,H-5’,H-6’and C=CH),6.99(s,1H,H-4),4.00(s,3H,OCH3),3.98(s,2H,H-3),3.95(s,3H,OCH3),3.63(s,2H,benzylic-CH2),2.53-2.56(q,4H,J=7.2Hz,2×CH2),1.06-1.10(t,6H,J=7.2Hz,2×CH3);IR(KBr):3071,2967,2932,1681,1630,1605,1588,1501,1305,1233,804,691cm-1.
实施例30:5,6-二甲氧基-2-(3-吡咯烷-1-基甲基-苯亚甲基)-1-茚酮
操作过程同实施例29,只是用3-吡咯烷-1-基甲基-苯甲醛代替3-二乙胺基甲基-苯甲醛,得到0.30g淡黄色固体,收率82.6%,熔点:112~113℃;1H-NMR(δ,CDCl3):7.61(s,2H,H-7and H-2’),7.55-7.57(d,1H,J=7.2Hz,H-4’),7.36-7.43(m,3H,H-5’,H-6’and C=CH),7.00(s,1H,H-4),4.01(s,3H,OCH3),3.99(s,2H,H-3),3.97(s,3H,OCH3),3.69(s,2H,benzylic-CH2),2.56(m,4H,pyrrolidine-CH2,H-2”and H-5”),1.82(m,4H,H-3”and H-4”);IR(KBr):3064,2960,2825,1689,1630,1601,1585,1234,809,688cm-1.
实施例31:5,6-二甲氧基-2-(3-哌啶-1-基甲基-苯亚甲基)-1-茚酮
操作过程同实施例29,只是用3-哌啶-1-基甲基-苯甲醛代替3-二乙胺基甲基-苯甲醛,得到0.32g淡黄色固体,收率84.9%,熔点:127~129℃:1H-NMR(δ,CDCl3):7.61(s,2H,H-7and H-2’),7.54-7.56(d,1H,J=6.8Hz,H-4’),7.35-7.41(m,3H,H-5’,H-6’and C=CH),6.99(s,1H,H-4),4.01(s,3H,OCH3),3.98(s,2H,H-3),3.95(s,3H,OCH3),3.52(s,2H,benzylic-CH2),2.41(m,4H,piepridine-CH2,H-2”and H-6”),1.57-1.61(m,4H,H-3”and H-5”),1.45-1.46(m,2H,H-4”);IR(KBr):3068,2934,2851,1686,1628,1601,1584,1234,809,687cm-1.
实施例32:5,6-二甲氧基-2-(3-吗啉-4-基甲基-苯亚甲基)-1-茚酮
操作过程同实施例29,只是用3-吗啉-4-基甲基-苯甲醛代替3-二乙胺基甲基-苯甲醛,得到0.31g淡黄色固体,收率81.8%,熔点:157~159℃;1H-NMR(δ,CDCl3):7.63(s,1H,H-7),7.61(s,1H,H-2’),7.57-7.59(d,1H,J=7.6Hz,H-4’),7.39-7.43(t,1H,J=7.6Hz,H-5’),7.36-7.38(m,2H,H-6’and C=CH),7.01(s,1H,H-4),4.01(s,3H,OCH3),3.98(s,2H,H-3),3.96(s,3H,OCH3),3.73-3.76(m,4H,morpholine-CH2,H-2”and H-6”),3.56(s,2H,benzylic-CH2),2.49(m,4H,H-3”and H-5”);IR(KBr):3056,2979,2940,1687,1629,1601,1584,1509,1469,1234,810,690cm-1.
实施例33:5,6-二甲氧基-2-(4-二甲胺基甲基-苯亚甲基)-1-茚酮
操作过程同实施例27,只是用4-二甲胺基甲基-苯甲醛代替3-二甲胺基甲基-苯甲醛,得到0.27g淡黄色固体,收率80.1%,熔点:135~137℃,1H-NMR(δ,CDCl3):7.60-7.63(m,3H,H-7,H-2’and H-6’),7.39-7.41(d,2H,J=7.6Hz,H-3’and H-5’),7.36(s,1H,C=CH),6.99(s,1H,H-4),4.01(s,3H,OCH3),3.97(s,2H,H-3),3.96(s,3H,OCH3),3.47(s,2H,benzylic-CH2),2.27(s,6H,2×N-CH3);IR(KBr):3058,2924,2805,1690,1629,1605,1586,824cm-1.
实施例34:5,6-二甲氧基-2-(4-甲乙胺基甲基-苯亚甲基)-1-茚酮
操作过程同实施例27,只是用4-甲乙胺基甲基-苯甲醛代替3-二甲胺基甲基-苯甲醛,得到0.29g淡黄色固体,收率82.6%,熔点:105~107℃。1H-NMR(δ,CDCl3):7.58-7.62(m,3H,H-7,H-2’and H-6’),7.40-7.42(d,2H,J=8.4Hz,H-3’and H-5’),7.34(s,1H,C=CH),6.99(s,1H,H-4),4.00(s,3H,OCH3),3.96(s,2H,H-3),3.95(s,3H,OCH3,3.53(s,2H,benzylic-CH2),2.45-2.50(q,4H,J=7.2Hz,CH2-CH3),2.22(s,3H,N-CH3),1.10-1.14(t,3H,J=7.2Hz,CH2-CH3);IR(KBr):3063,2969,2836,1683,1629,1606,1590,1501,837cm-1.
实施例35:5,6-二甲氧基-2-(4-二乙胺基甲基-苯亚甲基)-1-茚酮
操作过程同实施例29,只是用4-二乙胺基甲基-苯甲醛代替3-二乙胺基甲基-苯甲醛,得到0.28g淡黄色固体,收率76.7%,熔点:116~118℃;1H-NMR(δ,CDCl3):7.60-7.62(m,3H,H-7,H-2’and H-6’),7.42-7.44(d,2H,J=7.6Hz,H-3’and H-5’),7.36(s,1H,C=CH),6.99(s,1H,H-4),4.00(s,3H,OCH3),3.97(s,2H,H-3),3.96(s,3H,OCH3),3.61(s,2H,benzylic-CH2),2.52-2.57(q,4H,J=7.2Hz,2×CH2,),1.05-1.08(t,6H,J=7.2Hz,2×CH3);IR(KBr):3061,2967,2932,1690,1629,1606,1500,1223,832cm-1.
实施例36:5,6-二甲氧基-2-(4-吡咯烷-1-基甲基-苯亚甲基)-1-茚酮
操作过程同实施例29,只是用4-吡咯烷-1-基甲基-苯甲醛代替3-二乙胺基甲基-苯甲醛,得到0.28g淡黄色固体,收率77.1%,熔点:138~140℃。1H-NMR(δ,CDCl3):7.60-7.63(m,3H,H-7,H-2’and H-6’),7.42-7.44(d,2H,J=8.0Hz,H-3’and H-5’),7.35(s,1H,C=CH),6.99(s,1H,H-4),4.00(s,3H,OCH3),3.97(s,2H,H-3),3.96(s,3H,OCH3),3.66(s,2H,benzylic-CH2),2.54(m,4H,pyrrolidine-CH2,H-2”and H-5”),1.81(m,4H,H-3”and H-4”);IR(KBr,cm-1):3066,2969,2928,1682,1628,1606,1590,1224,826cm-1.
实施例37:5,6-二甲氧基-2-(4-哌啶-1-基甲基-苯亚甲基)-1-茚酮
操作过程同实施例29,只是用4-吡咯烷-1-基甲基-苯甲醛代替3-二乙胺基甲基-苯甲醛,得到0.31g淡黄色固体,收率82.2%,熔点:124~126℃。1H-NMR(δ,CDCl3):7.59-7.61(m,3H,H-7,H-2’and H-6’),7.40-7.42(d,2H,J=7.6Hz,H-3’and H-5’),7.34(s,1H,C=CH),6.98(s,1H,H-4),4.00(s,3H,OCH3),3.95(s,5H,H-3and OCH3),3.52(s,2H,benzylic-CH2),2.38-2.41(m,4H,piperidine-CH2,H-2”and H-6”),1.57-1.61(m,4H,H-3”and H-5”),1.44(m,2HH-4”);IR(KBr):3064,2969,2933,2852,1689,1633,1606,1589,1222,863cm-1.
实施例38:5,6-二甲氧基-2-(4-吗啉-4-基甲基-苯亚甲基)-1-茚酮
操作过程同实施例29,只是用4-吗啉-4-基甲基-苯甲醛代替3-二乙胺基甲基-苯甲醛,得到0.32g淡黄色固体,收率84.4%,熔点:150~152℃。1H-NMR(δ,CDCl3):7.60-7.63(m,3H,H-7,H-2’and H-6’),7.41-7.43(d,2H,J=7.2Hz,H-3’and H-5’),7.36(s,1H,C=CH),6.99(s,1H,H-4),4.01(s,3H,OCH3),3.97(s,2H,H-3),3.96(s,3H,OCH3),3.72-3.74(m,4H,morpholine-CH2,H-2”andH-6”),3.54(s,2H,benzylic-CH2),2.47(m,4H,H-3”and H-5”);IR(KBr):3070,2955,2859,1688,1629,1607,1590,1499,866cm-1.
实施例39:5,6-二甲氧基-2-(3-二甲胺基甲基-苯甲基)-1-茚酮
将0.17g(0.5mmol)5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮、10mL THF和8.5mg 5%Pd/C投入反应瓶中,抽真空通氢3次,室温下,常压氢化反应6小时,抽滤除去催化剂,减压回收溶剂,残留物用硅胶柱层析,洗脱剂为:石油醚∶乙酸乙酯∶三乙胺=10∶5∶1,得到92mg白色固体,收率54.1%,熔点:76~78℃,1H-NMR(δ,CDCl3):7.19-7.25(m,3H,H-7,H-2’and H-5’),7.14-7.16(d,2H,H-4’and H-6’,J=8.0Hz),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.91(s,3H,OCH3),3.35-3.45(m,3H,N-CH2-Ph and Ph-CH2-a),3.03-3.09(dd,1H,J1=16.4Hz,J2=7.6Hz H-3a),2.97-3.02(m,1H,H-2),2.75-2.79(d,1H,J=16.4Hz,H-3e),2.62-2.68(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2-e),2.23(s,6H,2N-CH3);IR(KBr):3073,2927,2852,1681,1606,1591,1501,1455,780,706cm-1.
实施例40:5,6-二甲氧基-2-(3-甲乙胺基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(3-甲乙胺基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮,得到103mg白色固体,收率58.4%,熔点:68~69℃;1H-NMR(δ,CDCl3):7.22-7.24(d,1H,J=7.6Hz,H-4’),7.20-7.21(m,2H,H-7and H-2’),7.12-7.17(m,2H,H-6’and H-5’),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.57(m,2H,N-CH2-Ph),3.34-3.39(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-a),3.04-3.10(dd,1H,J1=16.4Hz,J2=7.2Hz,H-3a),2.96-3.02(m,1H,H-2),2.75-2.80(dd,1H,J1=16.4Hz,J2=2.8Hz,H-3e),2.62-2.68(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2-e),2.42-2.48(q,2H,J=7.2Hz,CH2-CH3),2.18(s,3H,N-CH3),1.09-1.12(t,3H,J=7.2Hz,CH2-CH3);IR(KBr):3056,2970,2931,2837,1681,1591,1502,1443,774,706cm-1.
实施例41:5,6-二甲氧基-2-(3-二乙胺基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(3-二乙胺基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚,得到106mg白色固体,收率57.8%,熔点:75~77℃,1H-NMR(δ,CDCl3):7.17-7.25(m,4H,H-7,H-2’,H-4’and H-5’),7.18-7.20(d,1H,J=7.6Hz,H-6’),6.80(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.55(s,2H,N-CH2-Ph),3.35-3.39(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2a),3.03-3.09(dd,1H,J1=16.4Hz,J2=7.2Hz,H-3a),2.97-3.02(m,1H,H-2),2.75-2.80(dd,1H,J1=16.4Hz,J2=2.8Hz,H-3e),2.61-2.67(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2e),2.48-2.53(q,4H,J=6.8Hz,2×CH2),1.02-1.05(t,6H,J=6.8Hz,2×CH3);13C-NMR(δ,CDCl3):206.5,155.4,149.3,148.9,140.0,139.5,129.3,129.2,128.2,127.2,126.8,107.3,104.3,57.4,56.1,56.0,49.0,46.6,37.2,31.8,11.6;ESI-MS:368(M+1);IR(KBr):3023,2967,2930,2871,1680,1605,1590,1502,1477,763,704cm-1.
实施例42:5,6-二甲氧基-2-(3-吡咯烷-1-基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(3-吡咯烷-1-基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮,得到114mg类白色固体,收率62.5%,熔点:79~81℃;1H-NMR(δ,CDCl3):7.19-7.24(m,4H,H-7,H-2’,H-4’and H-5’),7.13-7.15(d,1H,J=7.6Hz,H-6’),6.80(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.60-3.69(m,2H,N-CH2-Ph),3.33-3.37(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-a),3.04-3.10(dd,1H,J1=16.4Hz,J2=7.2Hz,H-3a),2.97-3.02(m,1H,H-2),2.75-2.79(dd,1H,J1=16.4Hz,J2=2.8Hz,H-3e),2.65-2.71(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2-e),2.54(m,4H,pyrrolidine-CH2,H-2”and H-5”),1.80(m,4H,H-3”and H-4”);IR(KBr):3075,2968,2927,1681,1606,1591,1502,1472,778,704cm-1.
实施例43:5,6-二甲氧基-2-(3-哌啶-1-基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(3-哌啶-1-基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮,得到123mg类白色固体,收率64.4%,熔点:81~83℃;1H-NMR(δ,CDCl3):7.16-7.23(m,4H,H-7,H-2’,H-4’and H-5’),7.11-7.13(d,1H,J=7.6Hz,H-6’),6.80(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.49(s,2H,N-CH2-Ph),3.34-3.38(dd,1H,J1=14.0Hz,J2=3.2Hz,Ph-CH2-a),3.04-3.10(dd,1H,J1=16.0Hz,J2=7.2Hz,H-3a,),2.97-3.02(m,1H,H-2),2.75-2.80(dd,1H,J1=16.4Hz,J2=2.4Hz,H-3e),2.63-2.69(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2-e),2.35(m,4H,piperidine-CH2,H-2”and H-6”),1.56-1.57(m,4H,H-3”and H-5”),1.42-1.43(m,2H,H-4”);IR(KB r1):3073,2927,2853,1682,1605,1591,1502,1472,1455,773,702cm-1.
实施例44:5,6-二甲氧基-2-(3-吗啉-4-基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(3-吗啉-4-基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮,得到108mg类白色固体,收率56.4%,熔点:108~109℃;1H-NMR(δ,CDCl3):7.23-7.25(d,1H,J=7.2Hz,H-4’),7.18-7.20(m,2H,H-7,H-2’),7.13-7.18(m,2H,H-5’and H-6’),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.69-3.72(m,4H,morpholine-CH2,H-2”and H-6”),3.45-3.51(s,2H,N-CH2-Ph),3.34-3.39(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-aO),3.04-3.10(dd,1H,J1=16.4Hz,J2=7.6Hz,H-3a),2.96-3.00(m,1H,H-2),2.74-2.79(dd,1H,J1=16.4Hz,J2=2.4Hz,H-3e),2.64-2.70(dd,1H,J1=14.0Hz,J2=10.0Hz,OPh-CH2-e),2.42(m,4H,H-3”and H-5”);IR(KBr):3021,2928,2858,1681,1594,1504,1477,779,707cm-1.
实施例45:5,6-二甲氧基-2-(4-二甲胺基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(4-二甲胺基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮,得到101mg类白色固体,收率59.6%,熔点:99~101℃;1H-NMR(δ,CDCl3):7.18-7.25(m,5H,H-7,H-2’,H-3’,H-5’and H-6’),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.41(s,2H,N-CH2-Ph),3.34-3.38(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-a),3.04-3.10(dd,1H,J1=16.4Hz,J2=7.6Hz,H-3a),2.96-3.01(m,1H,H-2),2.74-2.79(dd,1H,J1=16.4Hz,J2=3.2Hz,H-3e),2.61-2.67(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2-e),2.25(s,6H,2×N-CH3);IR(KBr):3073,2928,2853,1681,1605,1592,1502,1472,1454,805cm-1.
实施例46:5,6-二甲氧基-2-(4-甲乙胺基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(4-甲乙胺基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮,得到115mg类白色固体,收率65.2%,熔点:92~94℃;1H-NMR(δ,CDCl3):7.18-7.26(m,5H,H-7,H-2’,H-3’,H-5’and H-6’),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.50(s,2H,N-CH2-Ph),3.34-3.38(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-a),3.04-3.10(dd,1H,J1=16.8Hz,J2=7.6Hz,H-3a),2.96-3.00(m,1H,H-2),2.75-2.79(dd,1H,J1=16.8Hz,J2=2.4Hz,H-3e),2.61-2.67(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2-e),2.44-2.49(q,2H,J=7.2Hz,CH2-CH3),2.20(s,3H,N-CH3),1.09-1.13(t,3H,J=7.2Hz,CH2-CH3);IR(KBr):3072,2963,2926,2853,1682,1606,1592,1501,1455,820cm-1.
实施例47:5,6-二甲氧基-2-(4-二乙胺基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(4-二乙胺基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯甲基)-1-茚酮,得到106mg类白色固体,收率58.1%,熔点:98~100℃;1H-NMR(δ,CDCl3):7.24-7.26(d,2H,J=8.0Hz,H-2’and H-6’),7.17-7.20(m,3H,H-7,H-3’and H-5’),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.54(s,2H,N-CH2-Ph),3.34-3.38(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-a),3.04-3.10(dd,1H,J1=16.8Hz,J2=7.6Hz,H-3a),2.96-3.00(m,1H,H-2),2.75-2.79(dd,1H,J1=16.8Hz,J2=2.8Hz,H-3e),2.60-2.67(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2-e),2.49-2.55(q,4H,J=7.2Hz,2×CH2),1.02-1.06(t,6H,J=7.2Hz,2×CH3);IR(KBr):3073,2931,2874,1683,1606,1593,1505,1474,821cm-1.
实施例48:5,6-二甲氧基-2-(4-吡咯烷-1-基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(4-吡咯烷-1-基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯亚甲基)-1-茚酮,得到115mg类白色固体,收率63.0%,熔点:122~124℃;1H-NMR(δ,CDCl3):7.26-7.29(d,2H,J=8.0Hz,H-2’and H-6’),7.18-7.20(m,3H,H-7,H-3’and H-5’),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.65(s,2H,N-CH2-Ph),3.34-3.38(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-a),3.04-3.10(dd,1H,J1=16.4Hz,J2=7.2Hz,H-3a),2.95-3.00(m,1H,H-2),2.74-2.79(dd,1H,J1=16.4Hz,J2=3.2Hz,H-3e),2.61-2.67(dd,1H,J1=14.0Hz,J2=10.0Hz,Ph-CH2-e),2.58(m,4H,pyrrolidine-CH2,H-2”and H-5”),1.82(m,4H,H-3”and H-4”);IR(KBr):3072,2926,2852,1682,1605,1592,1502,1471,1454,863cm-1.
实施例49:5,6-二甲氧基-2-(4-哌啶-1-基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(4-哌啶-1-基甲基-苯亚甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯甲基)-1-茚酮,得到115mg类白色固体,收率60.4%,熔点:92~94℃;1H-NMR(δ,CDCl3):7.22-7.26(d,2H,J=8.0Hz,H-2’and H-6’),7.17-7.20(m,3H,H-7,H-3’and H-5’),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.65(s,2H,N-CH2-Ph),3.34-3.38(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-a),3.03-3.10(dd,1H,J1=16.8Hz,J2=7.2Hz,H-3a),2.96-3.00(m,1H,H-2),2.75-2.80(dd,1H,J1=16.4Hz,J2=2.8Hz,H-3e),2.59-2.65(dd,1H,J1=14.0Hz,J2=10.4Hz,Ph-CH2-e),2.36(m,4H,piperidine-CH2,H-2”and H-6”),1.54-1.58(m,4H,H-3”and H-5”),1.42-1.44(m,2H,H-4”);IR(KBr):3072,2936,2853,1681,1605,1591,1502,1472,1454,866cm-1.
实施例50:5,6-二甲氧基-2-(4-吗啉-4-基甲基-苯甲基)-1-茚酮
操作过程同实施例39,只是用5,6-二甲氧基-2-(4-吗啉-4-基甲基-苯甲基)-1-茚酮代替5,6-二甲氧基-2-(3-二甲胺基甲基-苯甲基)-1-茚酮,得到125mg类白色固体,收率65.3%,熔点:118~120℃;
1H-NMR(δ,CDCl3):7.18-7.25(m,5H,H-2’,H-3’,H-5’,H-6’and H-7),6.81(s,1H,H-4),3.94(s,3H,OCH3),3.92(s,3H,OCH3),3.70-3.72(m,4H,morpholine-CH2,H-2”and H-6”),3.48(s,2H,N-CH2-Ph),3.33-3.38(dd,1H,J1=14.0Hz,J2=4.0Hz,Ph-CH2-a),3.04-3.10(dd,1H,J1=16.8Hz,J2=7.6Hz,H-3a),2.96-3.00(m,1H,H-2),2.74-2.79(dd,1H,J1=16.8Hz,J2=3.2Hz,H-3e),2.61-2.67(dd,1H,J1=14.0Hz,J2=10.4Hz Ph-CH2-e),2.44(m,4H,H-3”andH-5”);IR(KBr,):3070,2994,2925,2857,1682,1605,1592,1501,1471,1455,866cm-1.
实施例51:体外抑制乙酰胆碱酯酶活性的测定:
乙酰胆碱酯酶酶源采用大鼠大脑皮层,以石杉碱甲为阳性对照,采用Ellman方法(Ellman,G.L.Courtney,K.D.Andres,V.Featherstone,R.M.A new and rapidcolormetric determination of acetylcholinesterase activity.Biochem Pharmacol.1961,7,88-95.),实验结果(为三次测试的平均值)参见表1。
表1 苯亚甲基茚酮和苄基茚酮类化合物的抑制乙酰胆碱酯酶活性数据
无需进一步详细阐述,相信采用前面所公开的内容,本领域技术人员可最大限度地应用本发明。因此,前面的实施方案应理解为仅是举例说明,而非以任何方式限制本发明的范围。
Claims (8)
2.根据权利要求1所述的苯亚甲基茚酮和苄基茚酮类衍生物,其特征是:当X=CH2和=CH时,当胺甲基在碳原子的间位取代时,N(R1R2)为二甲胺基、甲乙胺基、二乙胺基、吡咯烷基、哌啶基和吗啉基其中一种。
3.根据权利要求1所述的苯亚甲基茚酮和苄基茚酮类衍生物,其特征是:当X=CH2和=CH时,当胺甲基在碳原子的对位取代时,N(R1R2)为二甲胺基、甲乙胺基、二乙胺基、吡咯烷基、哌啶基和吗啉基其中一种。
4.根据权利要求1所述的苯亚甲基茚酮和苄基茚酮类衍生物的制备方法,其特征是由以下步骤实现:
以化合物I间甲基苯甲酸甲酯或对甲基苯甲酸甲酯为原料,用N-溴代丁二酰亚胺对苄位的甲基进行溴代,得到化合物II,然后用不同的二级胺进行取代反应,得到胺化产物III,再用氢化锂铝-二乙胺的复合试剂选择性还原苯甲酸酯得到取代苯甲醛IV,将它与5,6-二甲氧基茚酮在碱性条件下缩合制得苯亚甲基茚酮衍生物VI,最后经过催化氢化还原双键得到苄基茚酮衍生物VII。
5.根据权利要求4所述的苯亚甲基茚酮和苄基茚酮类衍生物的制备方法,其特征是:用N-溴代丁二酰亚胺对3-甲基-苯甲酸甲酯I的苄位甲基进行溴代,制得3-溴甲基-苯甲酸甲酯II,然后与二甲基胺、甲基乙基胺、二乙基胺、吡咯烷、哌啶、吗啉发生取代反应制得3-胺甲基苯甲酸甲酯III,再用氢化锂铝-二乙胺的复合试剂选择性还原制得中间体3-胺甲基-苯甲醛IV,在碱性试剂的作用下,将中间体IV与5,6-二甲氧基-1-茚酮V进行缩合反应制得3-胺甲基取代的苯亚甲基茚酮衍生物VI,最后用5%Pd/C氢化还原双键得到3-胺甲基取代的苄基茚酮衍生物VII。
6.根据权利要求4所述的苯亚甲基茚酮和苄基茚酮类衍生物的制备方法,其特征是:用N-溴代丁二酰亚胺对4-甲基-苯甲酸甲酯I的苄位甲基进行溴代,制得4-溴甲基-苯甲酸甲酯II,然后与二甲基胺、甲基乙基胺、二乙基胺、吡咯烷、哌啶、吗啉发生取代反应制得4-胺甲基苯甲酸甲酯III,再用氢化锂铝-二乙胺的复合试剂选择性还原制得中间体4-胺甲基-苯甲醛IV,在碱性试剂的作用下,将中间体IV与5,6-二甲氧基-1-茚酮V进行缩合反应制得4-胺甲基取代的苯亚甲基茚酮衍生物VI,最后用5%Pd/C氢化还原双键得到4-胺甲基取代的苄基茚酮衍生物VII。
7.根据权利要求1-6任一所述的苯亚甲基茚酮和苄基茚酮类衍生物,在制备治疗早老性痴呆疾病药物中的应用。
8.根据权利要求1-6任一所述苯亚甲基茚酮和苄基茚酮类衍生物,其特征是:其生理可接受的盐在制备治疗早老性痴呆疾病药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100504019A CN1277809C (zh) | 2005-06-22 | 2005-06-22 | 苯亚甲基茚酮和苄基茚酮类衍生物及制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100504019A CN1277809C (zh) | 2005-06-22 | 2005-06-22 | 苯亚甲基茚酮和苄基茚酮类衍生物及制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1709860A true CN1709860A (zh) | 2005-12-21 |
CN1277809C CN1277809C (zh) | 2006-10-04 |
Family
ID=35706156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100504019A Expired - Fee Related CN1277809C (zh) | 2005-06-22 | 2005-06-22 | 苯亚甲基茚酮和苄基茚酮类衍生物及制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1277809C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112745216A (zh) * | 2019-10-30 | 2021-05-04 | 常州锐博生物科技有限公司 | 一种4-溴甲基苯甲酸甲酯及其衍生物的制备方法 |
-
2005
- 2005-06-22 CN CNB2005100504019A patent/CN1277809C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112745216A (zh) * | 2019-10-30 | 2021-05-04 | 常州锐博生物科技有限公司 | 一种4-溴甲基苯甲酸甲酯及其衍生物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1277809C (zh) | 2006-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100335461C (zh) | 芳基磺酰基苯胺脲 | |
CN1036779C (zh) | 芳基环烷衍生物及其应用 | |
CN1861590A (zh) | 类黄酮衍生物及其制备方法和用途 | |
CN1163884A (zh) | 作为药物有效成分的二甲基-(3-芳基-丁-3-烯基)-胺化合物 | |
CN1434708A (zh) | 新的盐酸舍曲林多晶型物、其制备方法、含有它们的组合物和应用它们的方法 | |
CN86104539A (zh) | 羟基和烷氧基嘧啶类 | |
CN1015256B (zh) | 取代的苯基丁烯酰胺化合物的制备方法 | |
CN101062897A (zh) | 一种制备2,3-二氢-1h-茚-1-胺及其衍生物的改进方法 | |
CN87104099A (zh) | 抗变态反应和消炎药剂 | |
CN1277809C (zh) | 苯亚甲基茚酮和苄基茚酮类衍生物及制备方法和用途 | |
CN1082370C (zh) | 含有4-氧代-丁酸的药物组合物 | |
CN1019010B (zh) | 取代的β-二酮的制备方法 | |
CN101041646A (zh) | 含氮查耳酮衍生物的制备方法和用途 | |
CN1730460A (zh) | 一种一锅法制备咖啡酸酯衍生物的方法 | |
CN1518540A (zh) | 4-[4-[4-(羟基二苯基甲基)-1-哌啶基]-1-羟基丁基]-α,α-二甲基苯乙酸和其盐酸盐的新型结晶形式 | |
CN1095719A (zh) | 神经保护性3,4-二氢-2(1h)-喹诺酮类化合物 | |
CN1188405C (zh) | 新的吗啉代苯甲酰胺盐 | |
CN1023480C (zh) | 3-芳基-5-烷硫基-4h-1,2,4-三唑衍生物的制备方法 | |
CN1173968C (zh) | 卤代六羟基联苯衍生物的制法及药物用途 | |
CN1903833A (zh) | 一种制备托特罗定及其l-酒石酸盐的方法 | |
CN1037179C (zh) | 1,4-苯并噁嗪衍生物 | |
CN1333206A (zh) | 含有磺酰基二苯基吲哚化合物及其制法和药物用途 | |
CN1028994C (zh) | 1,3-双(三氟甲基)苯的锂化方法 | |
CN1156448C (zh) | 3-甲基芬太尼衍生物的光学异构体、合成及它们镇痛活性 | |
CN1526709A (zh) | 3,4,5-三取代-5-羟基-2(5氢)-呋喃酮化合物、合成方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061004 Termination date: 20120622 |